Barbara joined Rheos as our Chief Executive Officer, bringing more than 25 years of biopharmaceutical leadership expertise. She joins Rheos from Tilos Therapeutics, a biotech company developing antibody-based therapies for oncology and immune-mediated diseases, where she served as Chief Executive Officer and led the successful acquisition of the company by Merck in June of 2019. Previous positions include Entrepreneur-in-Residence at Partners Innovation Fund, Founder and Chief Executive Officer of Avaxia Biologics, Founder and Chief Scientific Officer of Recovery Pharmaceuticals, and VP, Discovery and Immunology at ImmuLogic Pharmaceutical Corp. Earlier in her career, Barbara was an Associate Professor of Rheumatology at the University of Maryland School of Medicine. Barbara trained as a post-doc in Cellular Immunology at the National Institutes of Health.
Barbara earned her A.B. in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from the Massachusetts Institute of Technology.